Smith & Nephew SNATS, Inc. $SNN Shares Bought by Moran Wealth Management LLC

Moran Wealth Management LLC raised its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 23.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 173,349 shares of the medical equipment provider’s stock after purchasing an additional 33,362 shares during the period. Moran Wealth Management LLC’s holdings in Smith & Nephew SNATS were worth $5,509,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SNN. River Road Asset Management LLC raised its position in shares of Smith & Nephew SNATS by 13.8% during the 4th quarter. River Road Asset Management LLC now owns 3,169,644 shares of the medical equipment provider’s stock worth $103,996,000 after purchasing an additional 384,926 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Smith & Nephew SNATS by 5.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,053,726 shares of the medical equipment provider’s stock worth $67,383,000 after buying an additional 100,697 shares in the last quarter. Bank of America Corp DE increased its position in Smith & Nephew SNATS by 139.9% during the third quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after buying an additional 575,666 shares in the last quarter. Todd Asset Management LLC raised its holdings in shares of Smith & Nephew SNATS by 30.2% in the fourth quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock worth $30,992,000 after acquiring an additional 219,348 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Smith & Nephew SNATS by 45.5% in the third quarter. BNP Paribas Financial Markets now owns 937,943 shares of the medical equipment provider’s stock worth $34,038,000 after acquiring an additional 293,418 shares during the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Up 0.0%

SNN stock opened at $30.26 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57. Smith & Nephew SNATS, Inc. has a 52-week low of $28.56 and a 52-week high of $38.79. The stock’s fifty day simple moving average is $30.30 and its 200-day simple moving average is $32.51.

Wall Street Analyst Weigh In

SNN has been the topic of several recent research reports. Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a research report on Monday, May 11th. Canaccord Genuity Group cut their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.